Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer

Summary

The primary objective of this open-label phase Ib trial is to determine the maximum tolerated dose and the recommended phase II dose for the combination of PF-03446962 plus regorafenib in patients with metastatic colorectal cancer. The secondary objectives are to describe the safety and tolerablility, and to describe the clinical activity of PF-03446962 plus regorafenib in terms of response rate and progression free survival

Timeline

Start

2014-08

Primary completion

2016-02

Completion

2016-05

Drugs

Indications